Erosive Esophagitis clinical trials

Explore recruiting erosive esophagitis clinical trials.

Recruiting erosive esophagitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Erosive Esophagitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AN EXPLORATORY, MULTICENTER, RANDOMIZED,DOUBLE BLIND STUDY OF CLINICAL OUTCOMES,TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS

Slovakia, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

Greece, Spain, Belgium, Italy, Lithuania, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Germany, Poland, Hungary, Bulgaria, Romania, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Erosive Esophagitis trials by city

Erosive Esophagitis in Toronto Erosive Esophagitis in Vancouver Erosive Esophagitis in Montreal Erosive Esophagitis in Calgary Erosive Esophagitis in Edmonton Erosive Esophagitis in Ottawa Erosive Esophagitis in Winnipeg Erosive Esophagitis in Quebec City Erosive Esophagitis in Hamilton Erosive Esophagitis in Kitchener Erosive Esophagitis in London Erosive Esophagitis in Halifax Erosive Esophagitis in New York Erosive Esophagitis in Los Angeles Erosive Esophagitis in Chicago Erosive Esophagitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease